Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONO-8539
- Development stage
- Phase 2
- Lead developer
- Ono Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ONO-8539 is a small molecule drug developed as a selective antagonist of the prostanoid EP1 receptor. It has been investigated in clinical trials for the treatment of non-erosive gastro-esophageal reflux disease (NERD) and overactive bladder syndrome. By blocking the EP1 receptor, ONO-8539 aims to reduce symptoms such as heartburn and urinary urgency associated with these conditions. The drug reached Phase 2 clinical trials for both indications but has not advanced further or received regulatory approval[1][2][3][6][7].
- Other names
- Benzoic acid, 4-(((2,3-dihydro-6-((2-methylpropyl)(2-thiazolylsulfonyl)amino)-1H-inden-5-yl)oxy)methyl)-3-methyl-
02
Targets
PTGER1 (Prostaglandin E Receptor 1)
Beyond the preview
Go deeper on ONO-8539.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONO-8539.